There is a lot of excitement about the use of mRNA technology to develop therapeutic cancer vaccines. The German firm BioNTech have four such vaccines undergoing Phase II trials at the moment.
Outside of the crisis-mode of pandemic vaccines, it usually takes years to get from Phase II to approval.
Will any of the ongoing BioNTech mRNA cancer vaccine trials proceed to Phase III trials in 2022?
If BioNTech declares during 2022 that any of its four ongoing Phase II trials into cancer vaccines (BNT111 for melanoma, BNT113 for head and neck cancer, BNT122 for melanoma and for colorectal cancer) will proceed to Phase III trials, this question will resolve positively. Otherwise it will resolve negatively.